Search

Displaying results 3691 - 3700 of 7540 in total
  1. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    However, with the introduction of newer drugs with fewer side effects, such as benzodiazepines, the clinical use of methyprylon is now limited. … Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.

  2. Drug

    R-30490

    go.drugbank.com/drugs/DB09179
    Experimental

    R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely … R-30490 is an opioid related to carfentanil used as an animal tranquilizer.

  3. Drug

    Adefovir dipivoxil

    go.drugbank.com/drugs/DB00718
    Approved

    Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective ag...

  4. Drug

    Cefotetan

    go.drugbank.com/drugs/DB01330
    ApprovedInvestigational

    The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

  5. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.

  6. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

  7. Drug

    Succinobucol

    go.drugbank.com/drugs/DB05399
    Investigational

    AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary

  8. Drug

    Sitimagene ceradenovec

    go.drugbank.com/drugs/DB04907
    Experimental

    It is being developed by Ark Therapeutics. … Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy

  9. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

  10. Drug

    Ascorbyl phosphate

    go.drugbank.com/drugs/DB11352
    ApprovedInvestigational

    C that is readily absorbed into the skin with a hydrating effect on the skin [A27212]. … These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% [A27211].